BCL2L1 and non-small cell lung carcinoma: In non-small cell lung cancer, on the other hand, this combination has been explored previously and one study found that combined treatment with osimertinib (EGFR inhibitor) and navitoclax (Bcl-2 and Bcl-xL inhibitor) caused synergistic inhibition on cell growth46, which is driven by BIM upregulation47.